XTalks
FEBRUARY 26, 2024
The class of IgE-mediated food allergies includes 160 foods, with peanuts, milk, eggs, wheat, soy and tree nuts being the most common ones. According to the Centers for Disease Control and Prevention (CDC), almost six percent of people in the US in 2021 had a food allergy. However, the treatment is restricted to peanut allergy.
pharmaphorum
NOVEMBER 8, 2021
A single dose of the COVID-19 monoclonal antibody therapy developing Regeneron reduced the risk of contracting the virus by around 82% for up to eight months, according to new trial data. The post One dose of Regeneron’s COVID antibody protects for eight months appeared first on. That was down from almost $2.6
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
DECEMBER 29, 2021
Sanofi and Regeneron have another challenger to their big-selling drug Dupixent for atopic dermatitis, now that the FDA has approved Leo Pharma’s rival antibody tralokinumab. It continues to grow strongly with Sanofi reporting a 53% rise in sales to more than $4.1 billion in the same year. billion in 2020. billion in 2020.
pharmaphorum
FEBRUARY 18, 2022
In CUPID STUDY B, IL-4 and IL-13 inhibitor Dupixent (dupilumab) wasn’t able to achieve a significant improvement in symptoms in Xolair-refractory CSU patients, and will be stopped for futility, although the antibody did show “numeric improvements” on itching and hive symptoms, according to its developers.
pharmaphorum
JULY 8, 2021
The FDA has started a priority review of AstraZeneca and Amgen’s severe asthma antibody tezepelumab, setting a date for a decision in the first quarter of 2022. Overall, the antibody cut the annual asthma exacerbation rate (AAER) by 56% over 52 weeks, which was consistent with the benefit seen in the phase 2 PATHWAY trial.
Drug Discovery World
NOVEMBER 9, 2023
Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Kielczewska will present: ‘Discovery of antibody-based therapeutics to challenging targets: Platform considerations’.
XTalks
AUGUST 2, 2023
Most of the company’s revenue comes from the manufacture and sale of biopharmaceutical products. billion in pharmaceutical sales from 2021. In contrast, several drugs experienced sale declines, such as Remicade (infliximab), an old immunology medication that continues to decline due to the rise of biosimilars since 2016.
Expert insights. Personalized for you.
100 
Let's personalize your content